Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oncogenesis

Showing results (191-200 of 1,005) with videos related to

Pageof 101
Sort By:
Oncogenesis|July 18, 2019
Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemiaClément Larrue, Quentin Heydt, Estelle Saland, et al.
Oncogenesis|January 24, 2017
The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cellsT Redmer, I Walz, B Klinger, et al.
Oncogenesis|February 27, 2021
Epigenetic regulation of TGF-β-induced EMT by JMJD3/KDM6B histone H3K27 demethylaseSu-Hyun Lee, Okhwa Kim, Hyo-Jin Kim, et al.
Oncogenesis|May 28, 2014
Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growthE Tsouko, A S Khan, M A White, et al.
Oncogenesis|September 12, 2024
Correction: Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of AxlJuliano D Paccez, Kristal Duncan, Durairaj Sekar, et al.
Oncogenesis|January 27, 2015
An internal ribosome entry site in the 5' untranslated region of epidermal growth factor receptor allows hypoxic expressionT E Webb, A Hughes, D S Smalley, et al.
Oncogenesis|July 22, 2022
Heterozygotic Brca1 mutation initiates mouse genome instability at embryonic stageXiaobing Wu, Maoni Guo, Jian Cui, et al.
Oncogenesis|April 15, 2022
Breast cancer in the era of integrating "Omics" approachesClaudia Rossi, Ilaria Cicalini, Maria Concetta Cufaro, et al.
Oncogenesis|April 14, 2019
TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcomaTeak-Jung Oh, Abhinav Adhikari, Trefa Mohamad, et al.
Oncogenesis|August 25, 2018
Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cellsEric Dietel, Alexander Brobeil, Claudia Tag, et al.
Pageof 101

Showing results (191-200 of 1,005) with videos related to

Sort By:
Pageof 101
Oncogenesis|July 18, 2019
Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemiaClément Larrue, Quentin Heydt, Estelle Saland, et al.
Oncogenesis|January 24, 2017
The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cellsT Redmer, I Walz, B Klinger, et al.
Oncogenesis|February 27, 2021
Epigenetic regulation of TGF-β-induced EMT by JMJD3/KDM6B histone H3K27 demethylaseSu-Hyun Lee, Okhwa Kim, Hyo-Jin Kim, et al.
Oncogenesis|May 28, 2014
Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growthE Tsouko, A S Khan, M A White, et al.
Oncogenesis|September 12, 2024
Correction: Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of AxlJuliano D Paccez, Kristal Duncan, Durairaj Sekar, et al.
Oncogenesis|January 27, 2015
An internal ribosome entry site in the 5' untranslated region of epidermal growth factor receptor allows hypoxic expressionT E Webb, A Hughes, D S Smalley, et al.
Oncogenesis|July 22, 2022
Heterozygotic Brca1 mutation initiates mouse genome instability at embryonic stageXiaobing Wu, Maoni Guo, Jian Cui, et al.
Oncogenesis|April 15, 2022
Breast cancer in the era of integrating "Omics" approachesClaudia Rossi, Ilaria Cicalini, Maria Concetta Cufaro, et al.
Oncogenesis|April 14, 2019
TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcomaTeak-Jung Oh, Abhinav Adhikari, Trefa Mohamad, et al.
Oncogenesis|August 25, 2018
Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cellsEric Dietel, Alexander Brobeil, Claudia Tag, et al.
Pageof 101